AI in Oncology by 2030 Strategy Lab
Designing resilient cancer care systems
Shaping the Future of Oncology with AI
Why Attend?
For Clinicians and Administrators
AI in Your Clinical Setting
AI tools are arriving faster than hospitals can integrate them. For oncology teams, AI adoption means deciding when a tool is clinically mature, what evidence is sufficient, how responsibility is documented, and how the tool changes diagnosis, treatment planning, follow-up, reporting or coordination of care. For hospital administrators, it means creating the conditions for use beyond a pilot. This includes the investment case, contracting, legal and operational risk, coordination between clinical, IT and data teams, data access, staff capacity and monitoring after deployment.
Work in the Strategy Lab
Participants will identify barriers inside cancer centres, compare implementation constraints and define priority actions for clinical teams, hospital management and decision-makers. The work will focus on practical conditions for adoption, including decision rights, reliable data, usable workflows, implementation capacity and governance after deployment.
Tools to Take You Forward
Participants will return to their organisations with a basis for evaluating AI tools in oncology, covering clinical evidence, workflow impact, data requirements, accountability, compliance and post-deployment monitoring. The workshop will also identify implementation approaches that can support internal decisions with clinical committees, hospital management, IT and data teams.
Contribute to the White Paper
The working groups’ conclusions will inform a post-event white paper. Reflecting the barriers, priorities and recommendations identified by participants, the white paper will focus on the practical conditions needed for AI adoption in oncology across European cancer care systems.
For Industry Professionals
Prepare for Europe’s 2030 requirements
The conditions for deploying AI in European oncology are changing. By 2030, companies will need to work within the European Health Data Space and the European Artificial Intelligence Act, alongside more demanding expectations for data governance, validation and cyber-readiness. The Strategy Lab will examine what these changes mean for product development, integration with hospital systems, responsibility after deployment and long-term support. Understanding these requirements early can reduce delays, limit costly redesign and strengthen collaboration with cancer centres.
Test Your Assumptions with the People Responsible for Implementation
The Strategy Lab brings industry into discussion with clinicians, hospital leaders, digital and data teams, researchers and public-sector experts. In the working groups, participants will compare their assumptions with the priorities and practical requirements of cancer centres and help define what an AI-ready cancer centre should have in place by 2030. For companies, this provides a practical basis for setting development priorities, identifying relevant partners and planning how AI solutions can be adopted and sustained in cancer care.
Contribute to the Final Recommendations
Industry participants will bring practical experience into the working groups. The post-event white paper will present the barriers; 2030 success conditions and recommendations identified during the Strategy Lab on what cancer centres need from industry to move AI beyond pilot projects.
The conditions for deploying AI in European oncology are changing. By 2030, companies will need to work within the European Health Data Space and the European Artificial Intelligence Act, alongside more demanding expectations for data governance, validation and cyber-readiness. The Strategy Lab will examine what these changes mean for product development, integration with hospital systems, responsibility after deployment and long-term support. Understanding these requirements early can reduce delays, limit costly redesign and strengthen collaboration with cancer centres.
Test Your Assumptions with the People Responsible for Implementation
The Strategy Lab brings industry into discussion with clinicians, hospital leaders, digital and data teams, researchers and public-sector experts. In the working groups, participants will compare their assumptions with the priorities and practical requirements of cancer centres and help define what an AI-ready cancer centre should have in place by 2030. For companies, this provides a practical basis for setting development priorities, identifying relevant partners and planning how AI solutions can be adopted and sustained in cancer care.
Contribute to the Final Recommendations
Industry participants will bring practical experience into the working groups. The post-event white paper will present the barriers; 2030 success conditions and recommendations identified during the Strategy Lab on what cancer centres need from industry to move AI beyond pilot projects.
Join the Evening Round Table
Registration for the Strategy Lab automatically registers you for the French-language round table event, “L'IA face au cancer : l'Europe a-t-elle les moyens de ses ambitions ?” (“AI and cancer: does Europe have the means to match its ambitions?”)
Listen to some of France’s leading decision-makers debate this question during the closing roundtable of the AI in Oncology by 2030 Strategy Lab, on 5 October 2026, on the Paris campus of EDHEC Business School.
Artificial intelligence in oncology is not short on promise, or evidence: early detection, support for therapeutic decision-making, care pathway optimization, reduced documentation burden. What's missing is scale.
The question is no longer whether AI can transform cancer care, but whether Europe is giving itself the means — regulatory, economic, organizational — to make that transformation happen.
Confirmed speakers include Antonello Forgione (IRCAD), Sophie Beaupère (Unicancer), David Gruson (Ethik-IA), Pauline Choné ( French Ministry of Health, Families, Autonomy and Persons with Disabilities) and Loick Menvielle (EDHEC Business School). The discussion will be moderated by Sébastien Marguerès (AI for Health & Artefact Adopt AI).
The panel discussion will be followed by a networking cocktail, offering an opportunity for researchers, clinicians, industry professionals, and innovation stakeholders to continue the debate and exchange.
Loick Menvielle
Director, Management in Innovative Health Chair
Antonello Forgione
Sophie Beaupère
Chief Executive Officer,
Unicancer
Pauline Choné
David Gruson
Founder & Director,
Ethik-IA
Sébastien Marguerès
About the Event
-
5 October 2026 -
EDHEC Paris Campus, 16-18 Rue du 4 septembre, 75002 Paris
The Programme
Meet Our Strategy Lab Experts
Pricing Details
How to get there?
Frequently asked questions
Is the event in person or online?
This is a 100% in-person event. We prioritise direct exchanges and networking to facilitate collaboration between participants, which is especially important during the small-group working sessions.
What is a "strategy lab"?
This programme is designed to go beyond high-level conference roundtables with expert-facilitated working groups on a dedicated topic. Before the event, participants will be provided a clear methodology outline for how to approach the challenge in order to best reach a quality outcome.
We feel this elevates this event above a simple workshop, enabling participants to develop a shared vision of priorities and key recommendations to make that vision real.
We feel this elevates this event above a simple workshop, enabling participants to develop a shared vision of priorities and key recommendations to make that vision real.
What are some of the participant profiles I will be working with?
Confirmed participants will be joining from the pharmaceutical industry, medical devices and innovation, clinicians, health insurance and data science.
